Usage Examples
- Health Canada issued the Notice of Compliance six weeks after the last clarification request.
- We cannot ship into Canada on the FDA approval alone; Health Canada needs its own new drug submission.
- Module 1 has to be rebuilt for Health Canada before that transaction will validate.
What is Health Canada?
Health Canada is the federal department that regulates drugs, medical devices, and other health products for the Canadian market, granting market authorization only through its own submission review rather than recognizing FDA or EMA approvals.
Health Canada exists because market authorization is a national act: no foreign regulator can make a product legal to sell in Canada. The department reviews the evidence itself, under Canadian statute, and issues the authorization that makes sale lawful. That is why a product cleared by FDA in March can still be unsellable in Toronto in December.
Health Canada covers the pre-market and post-market regulation of drugs, medical devices, natural health products, and other health products, through the Health Products and Food Branch. Health Canada does not decide clinical practice, hospital operations, physician licensing, or whether a provincial drug plan will reimburse a product. Authorization to sell and coverage to be paid for are separate decisions made by separate bodies.
Health Canada is applied in practice through discrete authorizations, each with its own trigger. A new drug needs a submission and a Notice of Compliance before sale or advertising. Any drug in dosage form needs a drug identification number. A Class II, III, or IV device needs a licence held by its manufacturer. Miss one and the product is not legally sellable, however complete the science file.
Not to be confused with
- FDA
- FDA authorizes for the United States only. An FDA approval creates no right to sell in Canada; Health Canada requires its own submission and its own notice of compliance before sale or advertising.
- HPFB (Health Products and Food Branch)
- HPFB is the branch inside Health Canada that reviews health-product submissions. Health Canada is the department; HPFB is the reviewing organization within it, so "filed with Health Canada" and "reviewed by HPFB" describe the same transaction.
- Notice of Compliance
- an NOC is the output of a Health Canada review, not the regulator itself. Health Canada also assigns DINs and issues device licences, each a separate permission with its own trigger and its own conditions.
- Drug identification number (DIN)
- a DIN is what permits a drug in dosage form to be sold; it is not a finding on safety and effectiveness. A new drug needs both a DIN and an NOC, and holding one does not imply the other.
The obligations are permission-by-permission, and each is a separate gate on the same product.
What you must do
- 1File a new drug submission with the Minister and obtain a notice of compliance before selling or advertising a new drug in CanadaC.08.002, Food and Drug Regulations
- 2Keep that notice of compliance in force, because the right to sell lapses while it is suspendedC.08.002, Food and Drug Regulations
- 3Obtain a drug identification number before selling any drug in dosage form, and confirm the assignment has not been cancelledC.01.014, Food and Drug Regulations
- 4Ensure the manufacturer holds a device licence, or an amended licence after a qualifying change, before any Class II, III, or IV medical device is imported or soldMedical Devices Regulations, SOR/98-282, s. 26
Common mistakes
Treating an FDA approval as a shortcut into Canada
teams set the Canadian launch date off the US decision and discover the Canadian filing has not started. Sale and advertising of a new drug are prohibited until Health Canada itself has issued a notice of compliance, so the Canadian clock runs independently and every month of slippage is lost revenue in a market you already have data for.
Reading a DIN as evidence of approval
a DIN is assigned so a drug in dosage form can be sold, not as a verdict on safety and effectiveness. Companies cite the DIN in partner diligence or investor material as "Health Canada approved," then cannot produce the notice of compliance when asked, which reads as either sloppiness or misrepresentation.
Leaving Class II devices out of the licensing plan
licence work gets budgeted for Class III and IV products while Class II is treated as administrative. The licence requirement covers Class II, III, and IV alike, and shipping before the manufacturer holds it is an unlicensed sale, not a paperwork gap to be closed retroactively.
When This Matters
- Health Canada issued the Notice of Compliance six weeks after the last clarification request.
- We cannot ship into Canada on the FDA approval alone; Health Canada needs its own new drug submission.
- Module 1 has to be rebuilt for Health Canada before that transaction will validate.
Frequently Asked Questions
A Notice of Compliance is the authorization Health Canada issues when a new drug submission is satisfactory, and it is what makes the drug legal to sell or advertise in Canada. The Food and Drug Regulations prohibit sale of a new drug until an NOC has been issued, and while it remains suspended.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
